CD274 and neoplasm: However, low PD-L1 expressing tumors can respond to checkpoint inhibition, while inversely, some patients with high PD-L1 levels do not, underscoring the need to better understand the mechanisms involved in the response to these agents (16), including tumor mutational burden and epigenetic dysregulations (11).